Market Overview

Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women's Health

Share:
  • Research collaboration aims to uncover new insights into ovarian
    biology and accelerate the development of personalized interventions
    in reproductive medicine and women's health
  • Research aims to explore individual differences in women's
    responses to IVF treatment, improve success rates, and reduce
    side-effects such as ovarian hyper-stimulation syndrome
  • Unique collaboration demonstrates Ferring and Celmatix's commitment
    to helping people build families worldwide by advancing science and
    women's health

Ferring Pharmaceuticals and Celmatix today announced an ambitious
genomics collaboration aimed at uncovering new insights into ovarian
biology and accelerating the development of personalized interventions
in reproductive medicine and women's health. This collaboration will
leverage both Ferring and Celmatix's significant expertise in women's
reproductive health and may unlock insights that could lead to novel
interventions with a broader impact on women's health.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180830005110/en/

The goal of this collaboration is to use insights from Celmatix's
proprietary knowledge base to explore whether women's responses to
ovarian stimulation during in vitro fertilisation (IVF), which
can vary greatly, are linked to individual characteristics of their
genome. These insights could help to reduce adverse and life-threatening
outcomes such as ovarian hyper-stimulation syndrome (OHSS), and lower
the rates of IVF cycle cancellation due to poor treatment response.

"We already have robust evidence that a woman's anti-Müllerian hormone
(AMH) levels can predict her response to IVF and enable a more
personalized approach to treatment," said Klaus Dugi, Chief Medical
Officer, Ferring Pharmaceuticals. "Through this unique collaboration
with Celmatix, we want to pave the way for even greater personalization
of care, with the ultimate aim of improving women's experience of
treatment and IVF success rates for families around the world."

"The demographic trends are clear that people are increasingly waiting
until later in life to become parents. Accordingly, advanced fertility
technologies like egg freezing and IVF are on the rise in the US and
globally. It is more important than ever to understand how a woman's
unique biology may impact her response to the treatments used for these
procedures," said Piraye Yurttas Beim, Founder and CEO of Celmatix.
"It's inspiring to collaborate with a forward-thinking company like
Ferring that is committed to bridging this knowledge gap and bringing
greater personalization to women's health."

Findings from the collaboration could potentially have an even bigger
long-term impact on women's health. In addition to her fertility and
reproductive health, a women's ovarian function underlies other
important aspects of her health, from age of menopause to cardiovascular
health, cognitive function, and risk for diseases such as cancer.

ENDS

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group committed to helping people around the world
build families and live better lives. Headquartered in Saint-Prex,
Switzerland, Ferring is a leader in reproductive medicine and women's
health, and in specialty areas within gastroenterology and urology.
Ferring has been developing treatments for mothers and babies for over
50 years and has a portfolio covering treatments from conception to
birth. Founded in 1950, privately-owned Ferring now employs
approximately 6,500 people worldwide, has its own operating subsidiaries
in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com,
or connect with us on Twitter,
Facebook,
Instagram,
LinkedIn
and YouTube.

About Celmatix Inc.

Celmatix is a next-generation women's health company transforming
reproductive health care through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them and their physicians
with more personalized information. The company's research-driven
products include the Fertilome® test, the world's first
multigene panel test that reveals what a woman's DNA says about her
reproductive health, Polaris®, a real-time predictive
analytics platform in use at leading fertility clinics across the U.S.,
which helps physicians optimize patient outcomes and improve the patient
experience, and MyFertility Compass™, a data-driven education tool that
gives women who are currently trying to conceive insights into their
fertility potential.

View Comments and Join the Discussion!